eHealth (EHTH) 10-Q 7 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 03, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-33071
Entity Registrant Name	EHEALTH, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	56-2357876
Entity Address, Address Line One	13620 RANCH ROAD 620 N, SUITE A250
Entity Address, City or Town	AUSTIN
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78717
City Area Code	737
Local Phone Number	248-2340
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	EHTH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		29,123,456
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001333493
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 174,986	$ 115,722
Short-term marketable securities	13,946	5,930
Accounts receivable	1,407	3,993
Contract assets – commissions receivable – current	203,013	244,663
Prepaid expenses and other current assets	11,006	12,044
Total current assets	404,358	382,352
Contract assets – commissions receivable – non-current	642,320	673,514
Property and equipment, net	4,228	4,864
Operating lease right-of-use assets	16,268	22,767
Restricted cash	3,090	3,090
Other assets	25,374	26,758
Total assets	1,095,638	1,113,345
Current liabilities:
Accounts payable	6,287	7,197
Accrued compensation and benefits	40,932	40,800
Accrued marketing expenses	9,404	20,340
Short term debt	68,196	0
Lease liabilities – current	7,206	7,070
Other current liabilities	14,019	3,131
Total current liabilities	146,044	78,538
Long-term debt	0	67,754
Deferred income taxes – non-current	28,305	29,687
Lease liabilities – non-current	26,285	28,333
Other non-current liabilities	4,789	4,949
Total liabilities	205,423	209,261
Commitments and contingencies (Note 8)
Convertible preferred stock	307,410	298,053
Stockholders’ equity:
Common stock	42	41
Additional paid-in capital	803,248	798,786
Treasury stock, at cost	(199,998)	(199,998)
Retained earnings (accumulated deficit)	(20,427)	7,284
Accumulated other comprehensive loss	(60)	(82)
Total stockholders’ equity	582,805	606,031
Total liabilities, convertible preferred stock and stockholders’ equity	$ 1,095,638	$ 1,113,345

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 92,964	$ 73,723
Operating costs and expenses:
Marketing and advertising	38,737	32,869
Customer care and enrollment	32,901	25,071
Technology and content	13,305	14,353
General and administrative	19,619	24,324
Impairment, restructuring and other charges	6,313	0
Total operating costs and expenses	110,875	96,617
Loss from operations	(17,911)	(22,894)
Interest expense	(2,809)	(2,580)
Other income, net	2,391	1,988
Loss before income taxes	(18,329)	(23,486)
Benefit from income taxes	(1,345)	(3,608)
Net loss	(16,984)	(19,878)
Preferred stock dividends	(5,480)	(5,101)
Change in preferred stock redemption value	(5,247)	(3,069)
Net loss attributable to common stockholders	$ (27,711)	$ (28,048)
Net loss per share attributable to common stockholders:
Basic (in dollars per share)	$ (0.96)	$ (1.01)
Diluted (in dollars per share)	$ (0.96)	$ (1.01)
Weighted-average number of shares used in per share amounts:
Basic (in shares)	28,912	27,648
Diluted (in shares)	28,912	27,648
Comprehensive loss:
Net loss	$ (16,984)	$ (19,878)
Unrealized holding gain (loss) on available for sale debt securities, net of tax	(23)	13
Foreign currency translation adjustments	45	110
Comprehensive loss	(16,962)	(19,755)
Commission
Revenue:
Total revenue	80,927	68,003
Other
Revenue:
Total revenue	$ 12,037	$ 5,720

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2022		39,977
Beginning balance at Dec. 31, 2022	$ 650,955	$ 40	$ 777,187	$ (199,998)	$ 73,799	$ (73)
Beginning balance (in shares) at Dec. 31, 2022				12,415
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity incentive plans (in shares)		160
Repurchase of shares to satisfy employee tax withholding obligations	(428)		(428)
Repurchase of shares to satisfy employee tax withholding obligations (in shares)				57
Dividends and accretion related to convertible preferred stock	(8,170)				(8,170)
Stock-based compensation	5,306		5,306
Other comprehensive income, net of tax	123					123
Net loss	(19,878)				(19,878)
Ending balance (in shares) at Mar. 31, 2023		40,137
Ending balance at Mar. 31, 2023	$ 627,908	$ 40	782,065	$ (199,998)	45,751	50
Ending balance (in shares) at Mar. 31, 2023	12,500			12,472
Beginning balance (in shares) at Dec. 31, 2023		41,457
Beginning balance at Dec. 31, 2023	$ 606,031	$ 41	798,786	$ (199,998)	7,284	(82)
Beginning balance (in shares) at Dec. 31, 2023				12,828
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity incentive plans (in shares)		545
Issuance of common stock in connection with equity incentive plans	1	$ 1
Repurchase of shares to satisfy employee tax withholding obligations	(1,256)		(1,256)
Repurchase of shares to satisfy employee tax withholding obligations (in shares)				172
Dividends and accretion related to convertible preferred stock	(10,727)				(10,727)
Stock-based compensation	5,718		5,718
Other comprehensive income, net of tax	22					22
Net loss	(16,984)				(16,984)
Ending balance (in shares) at Mar. 31, 2024		42,002
Ending balance at Mar. 31, 2024	$ 582,805	$ 42	$ 803,248	$ (199,998)	$ (20,427)	$ (60)
Ending balance (in shares) at Mar. 31, 2024	13,000			13,000

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating activities:
Net loss	$ (16,984)	$ (19,878)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	533	656
Amortization of internally developed software	3,873	4,589
Stock-based compensation expense	5,540	4,994
Deferred income taxes	(1,382)	(3,611)
Impairment charges	5,492	0
Other non-cash items	(75)	61
Changes in operating assets and liabilities:
Accounts receivable	2,586	1,605
Contract assets – commissions receivable	73,095	82,507
Prepaid expenses and other assets	460	(125)
Accounts payable	(937)	(1,493)
Accrued compensation and benefits	132	7,193
Accrued marketing expenses	(10,936)	(15,019)
Deferred revenue	8,080	(372)
Accrued expenses and other liabilities	1,284	(304)
Net cash provided by operating activities	70,761	60,803
Investing activities:
Capitalized internal-use software and website development costs	(2,286)	(2,164)
Purchases of property and equipment and other assets	(204)	(67)
Purchases of marketable securities	(13,797)	(22,009)
Proceeds from redemption and maturities of marketable securities	6,000	0
Net cash used in investing activities	(10,287)	(24,240)
Financing activities:
Repurchase of shares to satisfy employee tax withholding obligations	(1,255)	(428)
Principal payments in connection with leases	(4)	(11)
Net cash used in financing activities	(1,259)	(439)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	49	108
Net increase in cash, cash equivalents and restricted cash	59,264	36,232
Cash, cash equivalents and restricted cash at beginning of period	118,812	147,640
Cash, cash equivalents and restricted cash at end of period	$ 178,076	$ 183,872

Summary of Business and Signifi

Summary of Business and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Business and Significant Accounting Policies	Summary of Business and Significant Accounting Policies Description of Business – eHealth, Inc., a Delaware corporation, and its consolidated subsidiaries (collectively, “eHealth”) is a leading private online health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to expertly guide consumers through their health insurance enrollment and related options, when, where and how they prefer. Our platform leverages technology to solve a critical problem in a large and growing market by aiding consumers in what has traditionally been a complex, confusing, and opaque health insurance purchasing process. Our omnichannel consumer engagement platform differentiates our offering from other brokers and enables consumers to use our services online, by telephone with a licensed insurance agent, or benefit advisor, or through a hybrid online assisted interaction that includes live agent chat and co-browsing capabilities. We have created a consumer-centric marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual, family, small business and other ancillary health insurance products from over 180 health insurance carriers nationwide. Our plan recommendation tool curates this broad plan selection by analyzing customer health-related information against plan data for insurance coverage fit. This tool is supported by a unified data platform and is available to our ecommerce customers and our benefit advisors. We strive to be the most trusted partner to the consumer in their life’s journey through the health insurance market. Unless otherwise specified or required by the context, references in this Quarterly Report on Form 10-Q to “eHealth,” “the Company,” “we,” “us” or “our” mean eHealth, Inc. and its consolidated direct and indirect wholly-owned subsidiaries. Basis of Presentation – The accompanying Condensed Consolidated Balance Sheet as of March 31, 2024 and other condensed consolidated financial statements for the three months ended March 31, 2024 and 2023 are unaudited. The Condensed Consolidated Balance Sheet as of December 31, 2023 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on February 29, 2024. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. Certain prior period amounts have been reclassified to conform with our current period presentation. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023 and include all adjustments necessary for the fair presentation of our financial position as of March 31, 2024 and December 31, 2023 and our results of operations for the periods presented. The results for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2024 and therefore, should not be relied upon as an indicator of future results. Beginning in the first quarter of 2024, primarily as a result of vacating excess office space, we modified our methodology used in allocating certain expenses for the purpose of evaluating financial and segment performance and resource allocation. Specifically, we no longer allocate our facilities-related expenses, and as a result, these costs are now reported within the “General and administrative” line in our Condensed Consolidated Statements of Comprehensive Loss and within Corporate for our segment profit (loss). We have recast the Condensed Consolidated Statements of Comprehensive Loss and our segment profit (loss) for the prior period presented to conform to our current methodology. This resulted in a classification change of expenses from marketing and advertising, customer care and enrollment, and technology and content into general and administrative. Additionally, our segment profit (loss) no longer includes our facilities allocation to each of our segments and instead, these costs are included within Corporate. There was no impact to total operating costs and expenses, loss from operations, net loss or net loss per share attributable to common stockholders on our Condensed Consolidated Statements of Comprehensive Loss. Significant Accounting Policies, Estimates and Judgments – The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the fair value of investments, the commissions we expect to collect for each approved member cohort, valuation allowance for deferred income taxes, provision for (benefit from) income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates. There have been no material changes for the three months ended March 31, 2024 to our significant accounting policies discussed in our Annual Report on Form 10-K for the year ended December 31, 2023. Recently Adopted Accounting Pronouncements We did not adopt any new accounting pronouncements during the three months ended March 31, 2024. Recently Issued Accounting Pronouncements Not Yet Adopted Segment Reporting (Topic 280) — In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of a segment’s profit or loss. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements and early adoption is permitted. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and related disclosures. Income Taxes (Topic 740) — In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as additional disclosure on income taxes paid. The ASU is effective on a prospective basis for fiscal years beginning after December 15, 2024 for public entities and early adoption is permitted. We are currently evaluating the impact of adopting of this ASU on our consolidated financial statements and related disclosures.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Disaggregation of Revenue – The table below depicts the disaggregation of revenue by product and is consistent with how we evaluate our financial performance (in thousands): Three Months Ended 2024 2023 Medicare Medicare Advantage $ 61,996 $ 54,121 Medicare Supplement 5,478 4,065 Medicare Part D 2,685 777 Total Medicare 70,159 58,963 Individual and Family (1) Non-Qualified Health Plans 1,645 2,355 Qualified Health Plans 2,046 1,651 Total Individual and Family 3,691 4,006 Ancillary Short-term 388 984 Dental 877 710 Vision 689 210 Other 734 518 Total Ancillary 2,688 2,422 Small Business 3,616 4,873 Commission Bonus and Other 773 (2,261) Total Commission Revenue 80,927 68,003 Other Revenue Sponsorship and Advertising Revenue 10,189 4,020 Other 1,848 1,700 Total Other Revenue 12,037 5,720 Total Revenue $ 92,964 $ 73,723 _____________ (1) We define our individual and family plan offerings as major medical individual and family health insurance plans, which do not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both qualified and non-qualified plans. Qualified health plans meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans do not meet the requirements of the Affordable Care Act and are not offered through the government-run health insurance exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of non-qualified plans. Commission revenue by segment is presented in the table below (in thousands): Three Months Ended 2024 2023 Medicare Commission revenue from members approved during the period $ 69,752 $ 56,617 Net commission revenue from members approved in prior periods (1) 1,002 52 Total Medicare segment commission revenue $ 70,754 $ 56,669 Employer and Individual Commission revenue from members approved during the period $ 5,677 $ 6,708 Commission revenue from renewals of small business members during the period 3,028 3,113 Net commission revenue from members approved in prior periods (1) 1,468 1,513 Total Employer and Individual segment commission revenue $ 10,173 $ 11,334 Total commission revenue from members approved during the period $ 75,429 $ 63,325 Commission revenue from renewals of small business members during the period 3,028 3,113 Total net commission revenue from members approved in prior periods (1)(2) 2,470 1,565 Total commission revenue $ 80,927 $ 68,003 _____________ (1) These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustments to revenue within the relevant reporting period. The net adjustment revenue includes both increases as well as reductions in revenue for certain prior period cohorts. (2) The after-tax impact of total net commission revenue from members approved in prior periods for the three months ended March 31, 2024 and 2023 was $0.06 and $0.04 per basic and diluted share, respectively. The total reductions to revenue from members approved in prior periods were $0.5 million for the three months ended March 31, 2024. These reductions to revenue primarily relate to the Employer and Individual segment. There were no reductions to revenue from members approved in prior periods for the three months ended March 31, 2023.

Supplemental Financial Statemen

Supplemental Financial Statement Information	3 Months Ended
	Mar. 31, 2024
Balance Sheet Related Disclosures [Abstract]
Supplemental Financial Statement Information	Supplemental Financial Statement Information Cash, Cash Equivalents and Restricted Cash We consider all investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Cash and cash equivalents are stated at fair value. We also invest in marketable securities that are measured and recorded at fair value. See Note 4 – Fair Value Measurements for further discussion about our marketable securities. Our cash, cash equivalents and restricted cash balances are summarized as follows (in thousands): March 31, 2024 December 31, 2023 Cash $ 19,865 $ 7,114 Cash equivalents 155,121 108,608 Cash and cash equivalents 174,986 115,722 Restricted cash 3,090 3,090 Total cash, cash equivalents and restricted cash $ 178,076 $ 118,812 As of March 31, 2024 and December 31, 2023, we had $3.1 million of restricted cash which was classified as a non-current asset on our Condensed Consolidated Balance Sheets. This amount collateralizes letters of credit related to certain lease commitments. Contract Assets and Accounts Receivable We estimate an allowance for credit losses using relevant available information from internal and external sources, related to past events, current conditions and reasonable and supportable forecasts. Specifically, for the purpose of measuring the probability of default parameters, we utilize Capital IQ’s, Standard & Poor’s and Moody’s analytics. Our estimates of loss given default are determined by using our historical collections data as well as historical information obtained through our research and review of other insurance related companies. Our estimated exposure at default is determined by applying these internal and external data sources to our commissions receivable balances. As such, we apply an immediate reversion method and revert to historical loss information when computing our credit loss exposure. Credit loss expenses are assessed quarterly and included in the “General and administrative” line in our Condensed Consolidated Statements of Comprehensive Loss. There were no write-offs during the three months ended March 31, 2024 or for the year ended December 31, 2023. The change in the allowance for credit losses is summarized as follows (in thousands): March 31, 2024 December 31, 2023 Beginning balance $ 2,118 $ 2,398 Change in allowance (251) (280) Ending balance $ 1,867 $ 2,118 Our contract assets – commissions receivable activities, net of credit loss allowances, are summarized as follows (in thousands): Medicare Segment E&I Segment Total Beginning balance at December 31, 2023 $ 847,332 $ 70,845 $ 918,177 Commission revenue from members approved during the period 69,752 5,677 75,429 Commission revenue from renewals of small business members during the period — 3,028 3,028 Net commission revenue from members approved in prior periods 1,002 1,468 2,470 Cash receipts (143,722) (10,300) (154,022) Net change in credit loss allowance 230 21 251 Ending balance at March 31, 2024 $ 774,594 $ 70,739 $ 845,333 Credit Risk Our financial instruments that are exposed to concentrations of credit risk principally consist of cash, cash equivalents, marketable securities, contract assets – commissions receivable and accounts receivable. We invest our cash and cash equivalents with major banks and financial institutions and, at times, such investments are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Yuan Renminbi and are not insured by the U.S. federal government. The deposits in China were $3.9 million as of March 31, 2024. See Note 4 – Fair Value Measurements for additional information regarding our marketable securities. We do not require collateral or other security for either our contract assets or accounts receivable. Carriers that represented 10% or more of our total contract assets – commissions receivable and accounts receivable balances are summarized as follows: March 31, 2024 December 31, 2023 Humana 28 % 27 % UnitedHealthcare (1) 26 % 26 % Aetna (1) 16 % 16 % _____________ (1) Percentages include the carriers’ subsidiaries. Prepaid Expenses and Other Current Assets – Our prepaid expenses and other current assets are summarized as follows (in thousands): March 31, 2024 December 31, 2023 Prepaid software and maintenance contracts $ 5,876 $ 5,328 Prepaid licenses 2,007 2,739 Prepaid expenses 1,287 1,808 Prepaid insurance 849 1,436 Other current assets 987 733 Prepaid expenses and other current assets $ 11,006 $ 12,044

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements We define fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques we use to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We classify the inputs used to measure fair value into the following hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability. Our financial assets measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy as follows (in thousands): March 31, 2024 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 17,010 $ 17,010 $ — $ — $ 17,010 Commercial paper 110,718 — 110,718 — 110,718 Agency bonds 27,393 — 27,393 — 27,393 Short-term marketable securities Commercial paper 13,946 — 13,946 — 13,946 Total assets measured at fair value $ 169,067 $ 17,010 $ 152,057 $ — $ 169,067 December 31, 2023 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 11,576 $ 11,576 $ — $ — $ 11,576 Commercial paper 86,090 — 86,090 — 86,090 Agency bonds 10,942 — 10,942 — 10,942 Short-term marketable securities Agency bonds 5,930 — 5,930 — 5,930 Total assets measured at fair value $ 114,538 $ 11,576 $ 102,962 $ — $ 114,538 We endeavor to utilize the best available information in measuring fair value. Our money market funds are measured at fair value based on quoted prices in active markets and are classified as Level 1 within the fair value hierarchy. Our available for sale marketable securities, which include commercial paper and agency bonds with maturities of less than one year, are measured at fair value using quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs and are classified as Level 2 within the fair value hierarchy. There were no transfers between the hierarchy levels during either of the three months ended March 31, 2024 or the year ended December 31, 2023. The following table summarizes our cash equivalents and available for sale debt securities by contractual maturity (in thousands): As of March 31, 2024 As of December 31, 2023 Amortized Cost Fair Value Amortized Cost Fair Value Due in 1 year $ 169,130 $ 169,067 $ 114,577 $ 114,538 Unrealized gains and losses on available for sale debt securities that are not credit related are included in accumulated other comprehensive loss and summarized as follows (in thousands): March 31, 2024 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Cash equivalents Money market funds $ 17,010 $ — $ — $ 17,010 Commercial paper 110,773 — (55) 110,718 Agency bonds 27,393 — — 27,393 Short-term marketable securities Commercial paper 13,954 — (8) 13,946 Total $ 169,130 $ — $ (63) $ 169,067 December 31, 2023 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Cash equivalents Money market funds $ 11,576 $ — $ — $ 11,576 Commercial paper 86,132 — (42) 86,090 Agency bonds 10,940 2 — 10,942 Short-term marketable securities Agency bonds 5,929 1 — 5,930 Total $ 114,577 $ 3 $ (42) $ 114,538 As of March 31, 2024 and December 31, 2023, we had 41 and 20 securities, respectively, in a net unrealized loss position that were immaterial individually and in aggregate. We did not record any credit losses regarding our available for sale debt securities during the three months ended March 31, 2024 or the year ended December 31, 2023. We do not intend to sell these securities, and it is more likely than not that we will not be required to sell these securities before the recovery of their amortized cost basis. We recognized interest income of $2.2 million and $1.9 million for the three months ended March 31, 2024 and 2023, respectively.

Equity

Equity	3 Months Ended
	Mar. 31, 2024
Stockholders' Equity Note [Abstract]
Equity	Equity 2021 Inducement Plan – On September 22, 2021, the Company adopted an inducement plan (the “2021 Inducement Plan”), pursuant to which the Company reserved 0.4 million shares of its common stock (subject to customary adjustments in the event of a change in capital structure of the Company) to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, other than following a bona fide period of non-employment, as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules (“Nasdaq Rules”). In March 2022 and September 2022, the Company amended and restated its 2021 Inducement Plan to reserve an additional 0.5 million and 1.5 million shares of its common stock, respectively (as amended and restated, the “A&R 2021 Inducement Plan”). The 2021 Inducement Plan and its amendments were approved by our Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Rules, and the terms and conditions of the A&R 2021 Inducement Plan and awards to be granted thereunder are substantially similar to our stockholder-approved Amended and Restated 2014 Equity Incentive Plan. As of March 31, 2024, 2.0 million shares were issued under the A&R 2021 Inducement Plan. Stock Repurchase Programs – We had no stock repurchase activity during the three months ended March 31, 2024 or 2023 except for the repurchase of shares to satisfy employee tax withholding obligations. As of March 31, 2024 and 2023, we had a total o f 13.0 million and 12.5 million shares, respectively, held in treasury. As of March 31, 2024 and 2023, we had 2.3 million and 1.8 million shares, respectively, in treasury that were previously surrendered by employees to satisfy tax withholding due in connection with the vesting of certain restricted stock units as well as 10.7 million shares previously repurchased under our past repurchase programs. For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. Stock-Based Compensation Expense – Our stock-based compensation expense is summarized as follows by award types for the periods presented below (in thousands): Three Months Ended 2024 2023 Restricted stock units $ 4,636 $ 4,073 Performance-based stock units 407 604 Common stock options 400 254 Employee stock purchase program 97 63 Total stock-based compensation expense $ 5,540 $ 4,994 Related tax benefit recognized $ 1,312 $ 1,170 The following table summarizes stock-based compensation expense by operating function for the periods presented below (in thousands): Three Months Ended 2024 2023 Marketing and advertising $ 644 $ 455 Customer care and enrollment 524 605 Technology and content 974 905 General and administrative 3,398 3,029 Total stock-based compensation expense $ 5,540 $ 4,994 Amount capitalized for internal-use software 178 312 Total stock-based compensation $ 5,718 $ 5,306

Convertible Preferred Stock

Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2024
Temporary Equity Disclosure [Abstract]
Convertible Preferred Stock	Convertible Preferred Stock Pursuant to an investment agreement dated February 17, 2021 with Echelon Health SPV, LP (“H.I.G.”), an investment vehicle of H.I.G. Capital (the “H.I.G. Investment Agreement”), we issued and sold to H.I.G., in a private placement, 2,250,000 shares of Series A convertible preferred stock (the “Series A Preferred Stock”), par value $0.001 per share, at an aggregate purchase price of $225.0 million on April 30, 2021 (the “Closing Date”). We received $214.0 million in net proceeds from the private placement with H.I.G., net of sales commissions and certain transaction fees totaling $11.0 million. Our Series A Preferred Stock is considered temporary equity in our Condensed Consolidated Balance Sheets and we have determined there are no material embedded features that require recognition as a derivative asset or liability. The Series A Preferred Stock ranks senior to all other equity securities of the Company with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Dividends – Dividends initially accrued on the Series A Preferred Stock daily at 8% per annum on the stated value of $100 per share (the “Stated Value”), and were payable in kind (“PIK”) beginning on June 30, 2021 through the second anniversary of the Closing Date. Subsequent to the second anniversary of the Closing Date, dividends continue to accrue at 8% per annum, with 6% PIK and 2% payable in cash in arrears beginning on June 30, 2023. Dividends compound semiannually and are PIK and payable in cash in arrears, as applicable, on June 30 and December 31 of each year (each a “Dividend Payment Date”). PIK dividends are cumulative and are added to the Accrued Value. “Accrued Value” means, as of any date, with respect to any share of Series A Preferred Stock, the sum of the Stated Value per share plus, on each Dividend Payment Date, on a cumulative basis, all PIK dividends that have accrued on such share but that have not previously been added to the Accrued Value. A s of March 31, 2024 w e have accrued $1.4 million f or cash dividends as of March 31, 2024. T he Series A Preferred Stock participates, on an as-converted basis, in all dividends paid to the holders of our common stock. Conversion Rights – The Series A Preferred Stock is convertible at any time into common stock at a conversion rate equal to (i) the Accrued Value plus accrued PIK dividends that have not yet been added to the Accrued Value, (ii) divided by the conversion price as of the applicable conversion date (the “Conversion Price”). As of March 31, 2024, the Conversion Price is equal to $79.5861 per share. This Conversion Price is subject to further adjustment and the number of shares of common stock issuable upon conversion of the Series A Preferred Stock is subject to certain limitations, each as set forth in the Certificate of Designations of Series A Preferred Stock, as filed with the Secretary of State of the State of Delaware on April 30, 2021 (the “Certificate of Designations”). Redemption Put Right – At any time on or after the sixth anniversary of the Closing Date, holders of the Series A Preferred Stock will have the right to cause the Company to redeem all or any portion of the Series A Preferred Stock in cash at an amount equal to the greater of (i) 135% of the Accrued Value per share as of the redemption date, plus accrued PIK dividends that have not yet been added to the Accrued Value and (ii) the amount per share that would be payable on an as-converted basis on such Series A Preferred Stock at the then-current Accrued Value, plus accrued PIK dividends that have not yet been added to the Accrued Value, and in either case of (i) or (ii) plus any unpaid cash dividends that would have otherwise been settled in cash in connection with such conversion (the greater of (i) and (ii), the “Redemption Price”). Redemption Call Right – At any time on or after the sixth anniversary of the Closing Date, the Company will have the right (but not the obligation) to redeem out of legally available funds and for cash consideration all (but not less than all) of the Series A Preferred Stock upon at least 30 days prior written notice at an amount equal to the Redemption Price. Board Nomination Rights – H.I.G. is entitled to nominate one individual for election to our Board of Directors so long as it continues to own at least 30% of the common stock issuable or issued upon conversion of the Series A Preferred Stock originally issued to it in the private placement. Under certain circumstances, H.I.G. also has the right to nominate an additional individual to our Board of Directors if we fail to maintain certain levels of commissions receivable or liquidity as further discussed below. Voting Rights – The Series A Preferred Stock will vote together with the common stock as a single class on all matters submitted to a vote of the holders of the common stock (subject to certain voting limitations set forth in, and the terms and conditions of, the Certificate of Designations). Each holder of Series A Preferred Stock shall be entitled to the number of votes, rounded down to the nearest whole number, equal to the product of (i) the aggregate Accrued Value of the issued and outstanding shares of Series A Preferred Stock divided by $69.684, which is the “Minimum Price” computed in accordance with the Certificate of Designations (as further described below), multiplied by (ii) a fraction, the numerator of which is the number of shares of Series A Preferred Stock held by such holder and the denominator of which is the aggregate number of issued and outstanding shares of Series A Preferred Stock. “Minimum Price” means the lower of: (i) the Nasdaq Official Closing Price per share of common stock on the Closing Date; or (ii) the average Nasdaq Official Closing Price per share of common stock for the five trading days immediately prior to the Closing Date. Holders of Series A Preferred Stock will have one vote per share on any matter on which the holders of the Series A Preferred Stock are entitled to vote separately as a class (subject to certain voting limitations set forth in the Certificate of Designations). Mandatory Conversion of the Series A Preferred Stock – At any time on or after the third anniversary of the Closing Date, if the volume-weighted average price per share of our common stock is greater than 167.5% of the then-current Conversion Price for 20 consecutive trading days in a 30-day trading day period, the Company will have the right to convert all, but not less than all, of the Series A Preferred Stock into common stock at a conversion rate with respect to each share of Series A Preferred Stock of (i) the Accrued Value plus accrued PIK dividends that have not yet been added to the Accrued Value, (ii) divided by the then applicable Conversion Price. Covenants and Liquidity Requirements – As long as H.I.G. continues to own at least 30% of the Series A Preferred Stock originally issued to it in the private placement, the consent of H.I.G. will be required for the Company to incur certain indebtedness and to take certain other corporate actions as set forth in the H.I.G. Investment Agreement. In addition, the Company is required to maintain an Asset Coverage Ratio (as defined in the H.I.G. Investment Agreement) of at least 2.0x (the “Minimum Asset Coverage Ratio”), which increased to 2.5x in August of 2023. The first measurement date of the 2.5x Minimum Asset Coverage Ratio was September 30, 2023. Additionally, the H.I.G. Investment Agreement requires the Company to maintain a Minimum Liquidity Amount (as defined in the H.I.G. Investment Agreement) for certain periods that ranges from $65.0 million to $125.0 million. Failure to maintain the Minimum Asset Coverage Ratio or the Minimum Liquidity Amount as of the date or for the time period required by the H.I.G. Investment Agreement, for as long as H.I.G. continues to own at least 30% of the Series A Preferred Stock originally issued to it in the private placement, entitles H.I.G., subject to conditions and restrictions specified therein, to additional rights, including the right to nominate one additional member to the Company’s Board of Directors, the right to approve the Company’s annual budget, the right to approve hiring or termination of certain key executives and the right to approve the incurrence of certain indebtedness. As of September 30, 2023, we failed to maintain the Minimum Asset Coverage Ratio, which entitles H.I.G to the additional rights set forth above. On March 13, 2024, the Nominating and Corporate Governance Committee of our Board of Directors approved the appointment of a board observer designated by H.I.G. As of March 31, 2024, we were in compliance with the Minimum Liquidity Amount. As of March 31, 2024, the estimated Series A Preferred Stock redemption value equals 135% of the Accrued Value per share as of the redemption date, plus accrued PIK dividends that have not yet been added to the Accrued Value, which is significantly in excess of the fair value of the common stock into which the Series A Preferred Stock is convertible as of March 31, 2024. We have elected to apply the accretion method to adjust the carrying value of the Series A Preferred Stock to its redemption value at the earliest date of redemption, April 30, 2027. Amounts recognized to accrete the Series A Preferred Stock to its estimated redemption value are treated as a deemed dividend and are recorded as a reduction to retained earnings. The estimated redemption value will vary in subsequent periods due to the redemption put right described above and we have elected to recognize such changes prospectively. No shares of Series A Preferred Stock have been converted, and the Series A Preferred Stock was convertible into 3.5 million shares of common stock as of March 31, 2024. The following table summarizes the proceeds and changes to our Series A Preferred Stock (in thousands): Gross proceeds $ 225,000 Less: issuance costs (10,975) Net proceeds $ 214,025 Balance as of December 31, 2023 $ 298,053 Accrued paid-in-kind dividends 4,110 Change in preferred stock redemption value 5,247 Balance as of March 31, 2024 $ 307,410

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	Net Loss Per Share Attributable to Common Stockholders Our Series A Preferred Stock is considered a participating security which requires the use of the two-class method for the computation of basic and diluted per share amounts. Under the two-class method, earnings available to common stockholders for the period are allocated between common stockholders and participating securities according to dividends accumulated and participation rights in undistributed earnings. Net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holder of the Series A Preferred Stock does not have a contractual obligation to share in losses. Basic net loss attributable to common stockholders per share is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders per share is computed by dividing the net loss available to common stockholders for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net loss attributable to common stockholders per share reflects all potential dilutive common stock equivalent shares, including conversion of preferred stock, stock options, restricted stock units and shares to be issued under our employee stock purchase program. The following table sets forth the computation of basic and diluted net loss attributable to common stockholders per share (in thousands, except per share amounts): Three Months Ended 2024 2023 Numerator: Net loss attributable to common stockholders $ (27,711) $ (28,048) Denominator: Shares used in per share calculation – basic 28,912 27,648 Dilutive effect of common stock — — Shares used in per share calculation – diluted 28,912 27,648 Net loss attributable to common stockholders per share – basic and diluted $ (0.96) $ (1.01) For each of the three months ended March 31, 2024 and 2023, we had securities outstanding that could potentially dilute net loss per share, but the shares from the assumed conversion or exercise of these securities were excluded in the computation of diluted net loss per share as their effect would have been anti-dilutive. The number of weighted-average outstanding anti-dilutive shares that were excluded from the computation of diluted net loss per share consisted of the following (in thousands): Three Months Ended 2024 2023 Convertible preferred stock 3,469 3,256 Restricted stock units 2,204 1,774 Performance-based stock units 97 98 Common stock options 218 226 Employee stock purchase program 8 41 Total 5,996 5,395

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Service and Licensing Obligations We have entered into service and licensing agreements with third party vendors to provide various services, including network access, equipment maintenance and software licensing. As the benefits of these agreements are experienced uniformly over the applicable contractual periods, we record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. Our future minimum payments under non-cancellable contractual service and licensing obligations as of March 31, 2024 were as follows (in thousands): For the Years Ending December 31, 2024 (remainder) $ 3,784 2025 1,141 2026 — 2027 — 2028 — Thereafter — Total $ 4,925 Operating Leases Refer to Note 10 – Leases for commitments related to our operating leases. Self-Insurance We provide comprehensive major medical benefits to our employees. Effective January 1, 2023, we began maintaining a substantial portion of our U.S. employee health insurance benefits on a self-insured basis with up to $0.3 million per individual per year and a maximum claim liability of $22.5 million. As a result, we record a self-insurance liability based on claims filed and an estimate of claims incurred but not yet reported. As of March 31, 2024 and December 31, 2023, we had a self-insurance liability balance of $2.0 million and $2.5 million, respectively, in the “Accrued compensation and benefits” line on our Condensed Consolidated Balance Sheet. Contingencies From time to time, we receive inquiries from governmental bodies and also may be subject to various legal proceedings and claims arising in the ordinary course of business. We assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our condensed consolidated financial statements. An estimated loss contingency is accrued in the condensed consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings or other contingencies could result in material costs, even if we ultimately prevail, and we may from time to time enter into settlements to resolve such litigation. Legal costs incurred in connection with the resolution of claims, lawsuits and other contingencies generally are expensed as incurred. There were no material litigation-related accruals recorded during the three months ended March 31, 2024 or 2023. The following discussion is limited to the Company's material on-going legal proceedings: Legal Proceedings Derivative Actions – On July 7, 2020, a derivative lawsuit captioned Chernet v. Flanders et al., Case No. 3:20-cv-04477-SK (N.D. Cal.) (the “Chernet” matter) was filed in the United States District Court for the Northern District of California. On October 13, 2020, a derivative lawsuit captioned Lincolnshire Police Pension Fund v. Flanders et al., Case No. 20CV371555 (Cal. Super. Ct.) (the “Lincolnshire” matter) was filed in the Superior Court of California, County of Santa Clara. The complaints were brought against the Company’s then-chief executive officer, Mr. Flanders, its then-chief financial officer, Mr. Yung, its then-chief operating officer, Mr. Francis, and the then-current members of the Board of Directors (collectively, the “Individual Defendants”), and name the Company as a nominal defendant. The complaints allege, among other things, that the Individual Defendants made or caused the Company to make materially false and misleading statements and/or failed to disclose material information regarding the Company’s accounting and modeling assumptions, rate of member churn, profitability and internal controls for the period of March 2018 through the present. The Chernet and Lincolnshire complaints purport to assert claims for breach of fiduciary duty, unjust enrichment and waste of corporate assets. The Chernet lawsuit also alleges that the Individual Defendants violated Sections 14(a), 10(b), and 20(a) of the Exchange Act and asserts claims for abuse of control and gross mismanagement. The Chernet and Lincolnshire complaints seek damages, restitution, attorneys’ fees and costs, and certain measures with respect to the Company’s corporate governance and internal procedures, and (in the Lincolnshire lawsuit) equitable and/or injunctive relief. On August 12, 2020, the court stayed the Chernet matter pending the resolution of the then-anticipated motion to dismiss the consolidated securities class action. On December 11, 2020, the court stayed the Lincolnshire matter, also pending the resolution of the motion to dismiss in the consolidated securities class action. On October 5, 2021, a third derivative lawsuit, captioned Badwal v. Flanders et al., Case No. 4:21-cv-07795 (N.D. Cal.) (the “Badwal” matter) was filed in the United States District Court for the Northern District of California. The Badwal complaint purports to assert a claim for breach of fiduciary duty, an insider trading claim, and violations of Section 14(a), 10(b) and 21D of the Exchange Act. The Badwal complaint seeks damages, declaratory relief, corporate governance measures, equitable and injunctive relief, restitution and disgorgement, and attorneys’ fees and costs. On November 29, 2021, the federal court consolidated the Chernet and Badwal matters under the caption In re eHealth, Inc. Stockholder Derivative Litigation (the “Federal Derivative Action”). On August 12, 2021, the court granted-in-part and denied-in-part defendants’ motion to dismiss the securities class action. In December 2021, the parties entered into a stipulation to further stay the Federal Derivative Action pending the appointment of a new lead plaintiff in the securities class action, which was so ordered by the court on December 14, 2021. As discussed above, on November 9, 2022, the court appointed a new lead plaintiff in the securities class action. On December 9, 2022, plaintiffs in the Federal Derivative Action filed a verified consolidated stockholder derivative complaint on behalf of the Company against certain current and former members of its Board of Directors and certain of its officers. The complaint alleges breaches of fiduciary duties, insider trading, and violations of Sections 14(a), 10(b) and 21D of the Exchange Act. The complaint seeks damages, declaratory relief, corporate governance measures, equitable and injunctive relief, restitution and disgorgement, and attorneys’ fees and costs. On January 3, 2023, pursuant to a joint stipulation, the court ordered all proceedings in the Federal Derivative Action stayed pending the resolution of the securities class action. On July 28, 2023, the Lincolnshire matter was stayed pending the resolution of the securities class action, pursuant to the parties’ stipulation. On January 10, 2024, the Court entered the parties’ stipulated order voluntarily dismissing the Federal Derivative Action. On February 29, 2024, the parties stipulated to the voluntary dismissal of the Lincolnshire matter, and on March 4, 2024, the Santa Clara County Court entered an order dismissing the matter without prejudice pursuant to the stipulation.

Segment and Geographic Informat

Segment and Geographic Information	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Operating Segments We report segment information based on how our chief executive officer, who is our CODM, regularly reviews our operating results, allocates resources and makes decisions regarding our business operations. We evaluate our business performance and manage our operations as two distinct operating segments: Medicare, and Employer and Individual. The performance measures of our segments include revenue and segment profit (loss). Please refer to Note 1 – Summary of Business and Significant Accounting Policies of the Notes to Consolidated Financial Statements in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2023 for our accounting policies relating to operating segments. Additionally, as indicated in Note 1 of this report, our results below reflect our updated methodology used in allocating certain expenses beginning in the first quarter of fiscal 2024, and results from the prior period presented have been recast to conform with the current period presentation. The results of our operating segments are summarized for the periods presented below (in thousands): Three Months Ended 2024 2023 Revenue: Medicare $ 82,388 $ 61,834 Employer and Individual 10,576 11,889 Total revenue $ 92,964 $ 73,723 Segment profit (loss): Medicare $ 8,309 $ (586) Employer and Individual 4,652 7,674 Segment profit 12,961 7,088 Corporate (14,613) (19,743) Stock-based compensation expense (5,540) (4,994) Depreciation and amortization (4,406) (5,245) Impairment, restructuring and other charges (6,313) — Interest expense (2,809) (2,580) Other income, net 2,391 1,988 Loss before income taxes $ (18,329) $ (23,486) There were no inter-segment revenue transactions for the periods presented. With the exception of contract assets – commissions receivable, which is presented by segment in Note 3 – Supplemental Financial Statement Information , our CODM does not separately evaluate assets by segment, and therefore, assets by segment are not presented. Geographic Information Our long-lived assets primarily consist of property and equipment, net and internally developed software. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area are summarized as follows (in thousands): March 31, 2024 December 31, 2023 United States $ 27,432 $ 29,419 China 247 281 Total $ 27,679 $ 29,700 Significant Customers Substantially all revenue for the three months ended March 31, 2024 and 2023 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue are summarized as follows: Three Months Ended 2024 2023 Humana 26 % 24 % Aetna (1) 23 % 6 % UnitedHealthcare (1) 15 % 22 % ____________ (1) Percentages include the carriers’ subsidiaries.

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Leases	Leases Our lease portfolio primarily consists of operating leases for office space and our leases have remaining lease terms of less than 2 years to 6 years. Certain of these leases have free or escalating rent payment provisions. We recognize lease expense on a straight-line basis over the terms of the leases, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. Most leases include options to renew, and the exercise of these options is at our discretion. Subsequent to becoming a remote first workplace in the third quarter of 2022, we executed several subleases of our office space in the United States. The subleases run through the remaining term of the primary leases. As of March 31, 2024, we expect to generate a total of $13.1 million in future sublease income through January 31, 2030. Sublease income is recorded on a straight-line basis as a reduction of lease expense in our Condensed Consolidated Statements of Comprehensive Loss. We test right-of-use assets when impairment indicators are present in accordance with the asset impairment provisions of Accounting Standards Codification 360, Property, Plant and Equipment. As part of our fiscal 2024 cost savings initiatives, we reassessed our occupied leased office space to identify excess space to vacate and potentially sublease. We also reassessed current market conditions in our previously vacated leased office spaces which have not yet been subleased. As a result, we determined impairment indicators were present and we performed impairment testing of our right-of-use assets. We utilized an income approach to value the asset groups by performing a discounted cash flow analysis and determined that the net carrying values exceeded the estimated discounted future cash flows expected to be derived from the properties based on Level 3 inputs, including current sublease market rent, future sublease market conditions and the discount rate. This resulted in a $5.5 million impairment charge related to our operating lease right-of-use assets and property, plant and equipment, which was reflected in the “Impairment, restructuring and other charges” line in our Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2024. See Note 11 – Impairment, Restructuring and Other Charges for further discussion about our asset impairment charges. The components of operating lease costs for the three months ended March 31, 2024 and 2023 were as follows (in thousands): Three Months Ended 2024 2023 Operating lease expense $ 1,737 $ 1,855 Operating sublease income (576) (577) Total operating lease cost $ 1,161 $ 1,278 Supplemental information related to our leases are as follows (dollars in thousands): Three Months Ended 2024 2023 Cash paid for amounts included in the measurement of operating lease liabilities $ 2,231 $ 2,102 March 31, 2024 December 31, 2023 Weighted-average remaining lease term (in years) of operating leases 4.6 4.8 Weighted-average discount rate used to recognize operating lease right-of-use-assets 5.7 % 5.7 % As of March 31, 2024, maturities of our operating lease liabilities are as follows (in thousands): Year ending December 31, 2024 (remainder) $ 6,663 2025 9,099 2026 7,594 2027 6,773 2028 4,998 Thereafter 3,204 Total lease payments (1) $ 38,331 Less imputed interest (4,840) Total $ 33,491 ____________ (1) Non-cancellable sublease proceeds for the remainder of 2024 and the years ending December 31, 2025, 2026, 2027, 2028 and thereafter of $1.8 million, $2.6 million, $2.7 million, $2.8 million, $2.8 million, and $1.0 million, respectively, are not included in the table above.

Impairment, Restructuring and O

Impairment, Restructuring and Other Charges	3 Months Ended
	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
Impairment, Restructuring and Other Charges	Impairment, Restructuring and Other Charges The following table details impairment, restructuring and other charges for each of the periods presented (in thousands): Three Months Ended 2024 2023 Asset impairment charges $ 5,492 $ — Restructuring and reorganization charges 821 — Impairment, restructuring and other charges $ 6,313 $ — Asset Impairment For the three months ended March 31, 2024, we recognized a non-cash, pre-tax asset impairment charge of $5.5 million related to several of our leased office spaces in the “Impairment, restructuring and other charges” line in our Condensed Consolidated Statements of Comprehensive Loss. This charge was comprised of $5.1 million of operating lease right-of-use asset impairments and $0.4 million of property and equipment impairment. Refer to Note 10 – Leases for additional information related to our lease impairment charges. Restructuring Our restructuring and reorganization costs and liabilities consist primarily of severance, transition and other related costs. The following table summarizes the cash-based restructuring and reorganization related liabilities (in thousands): Balance at December 31, 2023 $ — Restructuring and reorganization charges 821 Payments (180) Balance at March 31, 2024 $ 641 During the three months ended March 31, 2024, we recognized $0.8 million of pre-tax restructuring charges in the “Impairment, restructuring and other charges” line in our Condensed Consolidated Statements of Comprehensive Loss, primarily related to employee termination benefits as a result of our cost-reduction efforts. Substantially all of the restructuring charges are expected to be settled in cash and no equity awards were modified. As of March 31, 2024, we had a $0.6 million restructuring accrual on our Condensed Consolidated Balance Sheet.

Debt

Debt	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Debt	Debt On February 28, 2022, we entered into a term loan credit agreement with Blue Torch Finance LLC, as administrative agent and collateral agent, and other lenders party thereto (the “Original Credit Agreement”). On August 16, 2022, we entered into an amendment (the “Amendment”) to the Original Credit Agreement (as amended by the Amendment, the “Credit Agreement”). The Amendment replaced the LIBOR-based Adjusted Euro currency Rate (as defined in the Original Credit Agreement) with Adjusted Term SOFR (as defined in the Amendment) as a reference rate for loans under the Credit Agreement. The proceeds of the loans under the Credit Agreement may be used for working capital and general corporate purposes, to refinance our credit agreement with Royal Bank of Canada (“RBC”) and to pay fees and expenses in connection with the entry into the Credit Agreement. The Credit Agreement provides for a $70.0 million secured term loan credit facility. We incurred closing costs totaling $5.1 million, which were recorded as a direct deduction from the face amount of the loan on our Condensed Consolidated Balance Sheets. Total amortization of closing costs, or debt issuance costs, was $0.4 million for the three months ended March 31, 2024 and 2023, and is recorded in the “Interest expense” line in our Condensed Consolidated Statements of Comprehensive Loss. There were $1.8 million of unamortized issuance costs as of March 31, 2024. The carrying value of the term loan approximates the fair value, based on Level 2 inputs (observable market prices in less than active markets), as the interest rate is variable over the selected interest period and is similar to current rates at which we can borrow funds. The carrying value of the loan was $68.2 million as of March 31, 2024. The Original Credit Agreement bore interest, at our option, at either a rate based on the LIBOR for the applicable interest period or a base rate, in each case plus a margin. The base rate was the highest of the prime rate, the federal funds rates plus 0.50% and one month adjusted LIBOR plus 1.00%. The margin was 7.50% for LIBOR loans and 6.50% for base rate loans. After the Amendment, the loans under the Credit Agreement bear interest, at our option, at either a rate based on the Adjusted Term SOFR or a base rate, in each case plus a margin. The base rate is the highest of the prime rate, the federal funds rate plus 0.50% and three-month Adjusted Term SOFR plus 1.00%. The margin is 7.50% for Adjusted Term SOFR loans and 6.50% for base rate loans. As of March 31, 2024, the interest rate was 13.10%. For the three months ended March 31, 2024 and 2023 we incurred interest expense of $2.3 million and $2.2 million , respectively. Furthermore, as part of the Credit Agreement, we incur a $0.3 million fee per annum, payable annually. The outstanding obligations under the Credit Agreement are payable in full on the maturity date. The Credit Agreement matures in February 2025. We have the right to prepay the loans under the Credit Agreement in whole or in part at any time, subject, in the case of certain mandatory prepayments or any voluntary prepayment of the loans under the Credit Agreement after February 28, 2023, to an exit fee, which right we did not exercise. Our obligations under the Credit Agreement are guaranteed by certain of our material domestic subsidiaries and substantially all of our assets and the assets of such guarantors, in each case, subject to customary exclusion. Financial covenants in the Credit Agreement require that we maintain Liquidity (as defined in the Credit Agreement) at or above $25.0 million as of the last calendar day of any month. The Credit Agreement also requires that the outstanding amount as of the last calendar day of any month be less than 50% of our total contract assets - commissions receivable (i.e., both current and non-current commissions receivable). As of March 31, 2024, we were in compliance with our loan covenants.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The following table summarizes our benefit from income taxes and our effective tax rates for the periods presented below (in thousands, except effective tax rate): Three Months Ended 2024 2023 Loss before income taxes $ (18,329) $ (23,486) Benefit from income taxes (1,345) (3,608) Effective tax rate 7.3 % 15.4 % For the three months ended March 31, 2024, we recognized a benefit from income taxes of $1.3 million, representing an effective tax rate of 7.3%, which was lower than the statutory federal tax rate primarily due to stock-based compensation adjustments, non-deductible lobbying expenses and an increase in global intangible low-taxed income, partially offset by research and development credits and state taxes. For the three months ended March 31, 2023, we recognized a benefit from income taxes of $3.6 million, representing an effective tax rate of 15.4%, which was lower than the statutory federal tax rate primarily due to stock-based compensation adjustments and non-deductible lobbying expenses, partially offset by research and development credits and state taxes. Assessing the realizability of our deferred tax assets is dependent upon several factors, including the likelihood and amount, if any, of future taxable income in relevant jurisdictions during the periods in which those temporary differences become deductible. We forecast taxable income by considering available positive and negative evidence, including our history of operating income and losses and our financial plans and estimates that we use to manage the business. These assumptions require significant judgment about future taxable income. As a result, the amount of deferred tax assets considered realizable is subject to adjustment in future periods if estimates of future taxable income change. We continue to recognize our deferred tax assets as of March 31, 2024, as we believe it is more likely than not that such deferred tax assets will be realized, with the exception of certain net operating losses and credits for which there is increased uncertainty regarding our future taxable income and a lack of other sources of taxable income, which have a valuation allowance.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net loss	$ (16,984)	$ (19,878)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Business and Signi_2

Summary of Business and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Description of Business	Description of Business – eHealth, Inc., a Delaware corporation, and its consolidated subsidiaries (collectively, “eHealth”) is a leading private online health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to expertly guide consumers through their health insurance enrollment and related options, when, where and how they prefer. Our platform leverages technology to solve a critical problem in a large and growing market by aiding consumers in what has traditionally been a complex, confusing, and opaque health insurance purchasing process. Our omnichannel consumer engagement platform differentiates our offering from other brokers and enables consumers to use our services online, by telephone with a licensed insurance agent, or benefit advisor, or through a hybrid online assisted interaction that includes live agent chat and co-browsing capabilities. We have created a consumer-centric marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual, family, small business and other ancillary health insurance products from over 180 health insurance carriers nationwide. Our plan recommendation tool curates this broad plan selection by analyzing customer health-related information against plan data for insurance coverage fit. This tool is supported by a unified data platform and is available to our ecommerce customers and our benefit advisors. We strive to be the most trusted partner to the consumer in their life’s journey through the health insurance market.
Basis of Presentation	Basis of Presentation – The accompanying Condensed Consolidated Balance Sheet as of March 31, 2024 and other condensed consolidated financial statements for the three months ended March 31, 2024 and 2023 are unaudited. The Condensed Consolidated Balance Sheet as of December 31, 2023 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on February 29, 2024. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. Certain prior period amounts have been reclassified to conform with our current period presentation. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023 and include all adjustments necessary for the fair presentation of our financial position as of March 31, 2024 and December 31, 2023 and our results of operations for the periods presented. The results for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2024 and therefore, should not be relied upon as an indicator of future results. Beginning in the first quarter of 2024, primarily as a result of vacating excess office space, we modified our methodology used in allocating certain expenses for the purpose of evaluating financial and segment performance and resource allocation. Specifically, we no longer allocate our facilities-related expenses, and as a result, these costs are now reported within the “General and administrative” line in our Condensed Consolidated Statements of Comprehensive Loss and within Corporate for our segment profit (loss). We have recast the Condensed Consolidated Statements of Comprehensive Loss and our segment profit (loss) for the prior period presented to conform to our current methodology. This resulted in a classification change of expenses from marketing and advertising, customer care and enrollment, and technology and content into general and administrative. Additionally, our segment profit (loss) no longer includes our facilities allocation to each of our segments and instead, these costs are included within Corporate. There was no impact to total operating costs and expenses, loss from operations, net loss or net loss per share attributable to common stockholders on our Condensed Consolidated Statements of Comprehensive Loss.
Significant Accounting Policies, Estimates and Judgments	Significant Accounting Policies, Estimates and Judgments –
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements We did not adopt any new accounting pronouncements during the three months ended March 31, 2024. Recently Issued Accounting Pronouncements Not Yet Adopted Segment Reporting (Topic 280) — In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of a segment’s profit or loss. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements and early adoption is permitted. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and related disclosures. Income Taxes (Topic 740) — In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as additional disclosure on income taxes paid. The ASU is effective on a prospective basis for fiscal years beginning after December 15, 2024 for public entities and early adoption is permitted. We are currently evaluating the impact of adopting of this ASU on our consolidated financial statements and related disclosures.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue by Segment	The table below depicts the disaggregation of revenue by product and is consistent with how we evaluate our financial performance (in thousands): Three Months Ended 2024 2023 Medicare Medicare Advantage $ 61,996 $ 54,121 Medicare Supplement 5,478 4,065 Medicare Part D 2,685 777 Total Medicare 70,159 58,963 Individual and Family (1) Non-Qualified Health Plans 1,645 2,355 Qualified Health Plans 2,046 1,651 Total Individual and Family 3,691 4,006 Ancillary Short-term 388 984 Dental 877 710 Vision 689 210 Other 734 518 Total Ancillary 2,688 2,422 Small Business 3,616 4,873 Commission Bonus and Other 773 (2,261) Total Commission Revenue 80,927 68,003 Other Revenue Sponsorship and Advertising Revenue 10,189 4,020 Other 1,848 1,700 Total Other Revenue 12,037 5,720 Total Revenue $ 92,964 $ 73,723 _____________ (1) We define our individual and family plan offerings as major medical individual and family health insurance plans, which do not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both qualified and non-qualified plans. Qualified health plans meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans do not meet the requirements of the Affordable Care Act and are not offered through the government-run health insurance exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of non-qualified plans. Commission revenue by segment is presented in the table below (in thousands): Three Months Ended 2024 2023 Medicare Commission revenue from members approved during the period $ 69,752 $ 56,617 Net commission revenue from members approved in prior periods (1) 1,002 52 Total Medicare segment commission revenue $ 70,754 $ 56,669 Employer and Individual Commission revenue from members approved during the period $ 5,677 $ 6,708 Commission revenue from renewals of small business members during the period 3,028 3,113 Net commission revenue from members approved in prior periods (1) 1,468 1,513 Total Employer and Individual segment commission revenue $ 10,173 $ 11,334 Total commission revenue from members approved during the period $ 75,429 $ 63,325 Commission revenue from renewals of small business members during the period 3,028 3,113 Total net commission revenue from members approved in prior periods (1)(2) 2,470 1,565 Total commission revenue $ 80,927 $ 68,003 _____________ (1) These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustments to revenue within the relevant reporting period. The net adjustment revenue includes both increases as well as reductions in revenue for certain prior period cohorts. (2) The after-tax impact of total net commission revenue from members approved in prior periods for the three months ended March 31, 2024 and 2023 was $0.06 and $0.04 per basic and diluted share, respectively. The total reductions to revenue from members approved in prior periods were $0.5 million for the three months ended March 31, 2024. These reductions to revenue primarily relate to the Employer and Individual segment. There were no reductions to revenue from members approved in prior periods for the three months ended March 31, 2023.

Supplemental Financial Statem_2

Supplemental Financial Statement Information (Tables)	3 Months Ended
	Mar. 31, 2024
Balance Sheet Related Disclosures [Abstract]
Schedule of Cash, Cash Equivalents and Restricted Cash	Our cash, cash equivalents and restricted cash balances are summarized as follows (in thousands): March 31, 2024 December 31, 2023 Cash $ 19,865 $ 7,114 Cash equivalents 155,121 108,608 Cash and cash equivalents 174,986 115,722 Restricted cash 3,090 3,090 Total cash, cash equivalents and restricted cash $ 178,076 $ 118,812
Schedule of Cash, Cash Equivalents and Restricted Cash	Our cash, cash equivalents and restricted cash balances are summarized as follows (in thousands): March 31, 2024 December 31, 2023 Cash $ 19,865 $ 7,114 Cash equivalents 155,121 108,608 Cash and cash equivalents 174,986 115,722 Restricted cash 3,090 3,090 Total cash, cash equivalents and restricted cash $ 178,076 $ 118,812
Schedule of Change in Allowance for Credit Loss	The change in the allowance for credit losses is summarized as follows (in thousands): March 31, 2024 December 31, 2023 Beginning balance $ 2,118 $ 2,398 Change in allowance (251) (280) Ending balance $ 1,867 $ 2,118
Schedule of Contract Assets - Commissions Receivable	Our contract assets – commissions receivable activities, net of credit loss allowances, are summarized as follows (in thousands): Medicare Segment E&I Segment Total Beginning balance at December 31, 2023 $ 847,332 $ 70,845 $ 918,177 Commission revenue from members approved during the period 69,752 5,677 75,429 Commission revenue from renewals of small business members during the period — 3,028 3,028 Net commission revenue from members approved in prior periods 1,002 1,468 2,470 Cash receipts (143,722) (10,300) (154,022) Net change in credit loss allowance 230 21 251 Ending balance at March 31, 2024 $ 774,594 $ 70,739 $ 845,333
Schedule of Credit Risk	Carriers that represented 10% or more of our total contract assets – commissions receivable and accounts receivable balances are summarized as follows: March 31, 2024 December 31, 2023 Humana 28 % 27 % UnitedHealthcare (1) 26 % 26 % Aetna (1) 16 % 16 % _____________ (1) Percentages include the carriers’ subsidiaries.
Schedule of Prepaid Expenses and Other Current Assets	Our prepaid expenses and other current assets are summarized as follows (in thousands): March 31, 2024 December 31, 2023 Prepaid software and maintenance contracts $ 5,876 $ 5,328 Prepaid licenses 2,007 2,739 Prepaid expenses 1,287 1,808 Prepaid insurance 849 1,436 Other current assets 987 733 Prepaid expenses and other current assets $ 11,006 $ 12,044

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Classifications of Fair Value Hierarchy	We classify the inputs used to measure fair value into the following hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability.
Schedule of Financial Assets Measured at Fair Value on a Recurring Basis	Our financial assets measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy as follows (in thousands): March 31, 2024 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 17,010 $ 17,010 $ — $ — $ 17,010 Commercial paper 110,718 — 110,718 — 110,718 Agency bonds 27,393 — 27,393 — 27,393 Short-term marketable securities Commercial paper 13,946 — 13,946 — 13,946 Total assets measured at fair value $ 169,067 $ 17,010 $ 152,057 $ — $ 169,067 December 31, 2023 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 11,576 $ 11,576 $ — $ — $ 11,576 Commercial paper 86,090 — 86,090 — 86,090 Agency bonds 10,942 — 10,942 — 10,942 Short-term marketable securities Agency bonds 5,930 — 5,930 — 5,930 Total assets measured at fair value $ 114,538 $ 11,576 $ 102,962 $ — $ 114,538
Schedule of Contractual Maturities	The following table summarizes our cash equivalents and available for sale debt securities by contractual maturity (in thousands): As of March 31, 2024 As of December 31, 2023 Amortized Cost Fair Value Amortized Cost Fair Value Due in 1 year $ 169,130 $ 169,067 $ 114,577 $ 114,538
Schedule of Unrealized Gains and Losses	Unrealized gains and losses on available for sale debt securities that are not credit related are included in accumulated other comprehensive loss and summarized as follows (in thousands): March 31, 2024 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Cash equivalents Money market funds $ 17,010 $ — $ — $ 17,010 Commercial paper 110,773 — (55) 110,718 Agency bonds 27,393 — — 27,393 Short-term marketable securities Commercial paper 13,954 — (8) 13,946 Total $ 169,130 $ — $ (63) $ 169,067 December 31, 2023 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Cash equivalents Money market funds $ 11,576 $ — $ — $ 11,576 Commercial paper 86,132 — (42) 86,090 Agency bonds 10,940 2 — 10,942 Short-term marketable securities Agency bonds 5,929 1 — 5,930 Total $ 114,577 $ 3 $ (42) $ 114,538

Equity (Tables)

Equity (Tables)	3 Months Ended
	Mar. 31, 2024
Stockholders' Equity Note [Abstract]
Schedule of Stock-based Compensation Expense by Award Type	Our stock-based compensation expense is summarized as follows by award types for the periods presented below (in thousands): Three Months Ended 2024 2023 Restricted stock units $ 4,636 $ 4,073 Performance-based stock units 407 604 Common stock options 400 254 Employee stock purchase program 97 63 Total stock-based compensation expense $ 5,540 $ 4,994 Related tax benefit recognized $ 1,312 $ 1,170
Schedule of Stock-based Compensation Expense by Operating Function	The following table summarizes stock-based compensation expense by operating function for the periods presented below (in thousands): Three Months Ended 2024 2023 Marketing and advertising $ 644 $ 455 Customer care and enrollment 524 605 Technology and content 974 905 General and administrative 3,398 3,029 Total stock-based compensation expense $ 5,540 $ 4,994 Amount capitalized for internal-use software 178 312 Total stock-based compensation $ 5,718 $ 5,306

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2024
Temporary Equity Disclosure [Abstract]
Schedule of Convertible Preferred Stock	The following table summarizes the proceeds and changes to our Series A Preferred Stock (in thousands): Gross proceeds $ 225,000 Less: issuance costs (10,975) Net proceeds $ 214,025 Balance as of December 31, 2023 $ 298,053 Accrued paid-in-kind dividends 4,110 Change in preferred stock redemption value 5,247 Balance as of March 31, 2024 $ 307,410

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss attributable to common stockholders per share (in thousands, except per share amounts): Three Months Ended 2024 2023 Numerator: Net loss attributable to common stockholders $ (27,711) $ (28,048) Denominator: Shares used in per share calculation – basic 28,912 27,648 Dilutive effect of common stock — — Shares used in per share calculation – diluted 28,912 27,648 Net loss attributable to common stockholders per share – basic and diluted $ (0.96) $ (1.01)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The number of weighted-average outstanding anti-dilutive shares that were excluded from the computation of diluted net loss per share consisted of the following (in thousands): Three Months Ended 2024 2023 Convertible preferred stock 3,469 3,256 Restricted stock units 2,204 1,774 Performance-based stock units 97 98 Common stock options 218 226 Employee stock purchase program 8 41 Total 5,996 5,395

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Payments For Contractual Obligations	Our future minimum payments under non-cancellable contractual service and licensing obligations as of March 31, 2024 were as follows (in thousands): For the Years Ending December 31, 2024 (remainder) $ 3,784 2025 1,141 2026 — 2027 — 2028 — Thereafter — Total $ 4,925

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The results of our operating segments are summarized for the periods presented below (in thousands): Three Months Ended 2024 2023 Revenue: Medicare $ 82,388 $ 61,834 Employer and Individual 10,576 11,889 Total revenue $ 92,964 $ 73,723 Segment profit (loss): Medicare $ 8,309 $ (586) Employer and Individual 4,652 7,674 Segment profit 12,961 7,088 Corporate (14,613) (19,743) Stock-based compensation expense (5,540) (4,994) Depreciation and amortization (4,406) (5,245) Impairment, restructuring and other charges (6,313) — Interest expense (2,809) (2,580) Other income, net 2,391 1,988 Loss before income taxes $ (18,329) $ (23,486)
Schedule of Long Lived Assets by Geographical Areas	Long-lived assets by geographical area are summarized as follows (in thousands): March 31, 2024 December 31, 2023 United States $ 27,432 $ 29,419 China 247 281 Total $ 27,679 $ 29,700
Schedule of Revenue by Major Customers	Carriers representing 10% or more of our total revenue are summarized as follows: Three Months Ended 2024 2023 Humana 26 % 24 % Aetna (1) 23 % 6 % UnitedHealthcare (1) 15 % 22 % ____________ (1) Percentages include the carriers’ subsidiaries.

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Schedule of Lease Cost	The components of operating lease costs for the three months ended March 31, 2024 and 2023 were as follows (in thousands): Three Months Ended 2024 2023 Operating lease expense $ 1,737 $ 1,855 Operating sublease income (576) (577) Total operating lease cost $ 1,161 $ 1,278 Supplemental information related to our leases are as follows (dollars in thousands): Three Months Ended 2024 2023 Cash paid for amounts included in the measurement of operating lease liabilities $ 2,231 $ 2,102 March 31, 2024 December 31, 2023 Weighted-average remaining lease term (in years) of operating leases 4.6 4.8 Weighted-average discount rate used to recognize operating lease right-of-use-assets 5.7 % 5.7 %
Schedule of Operating Lease Maturities	As of March 31, 2024, maturities of our operating lease liabilities are as follows (in thousands): Year ending December 31, 2024 (remainder) $ 6,663 2025 9,099 2026 7,594 2027 6,773 2028 4,998 Thereafter 3,204 Total lease payments (1) $ 38,331 Less imputed interest (4,840) Total $ 33,491 ____________ (1) Non-cancellable sublease proceeds for the remainder of 2024 and the years ending December 31, 2025, 2026, 2027, 2028 and thereafter of $1.8 million, $2.6 million, $2.7 million, $2.8 million, $2.8 million, and $1.0 million, respectively, are not included in the table above.

Impairment, Restructuring and_2

Impairment, Restructuring and Other Charges (Tables)	3 Months Ended
	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
Schedule of Impairment, Restructuring and Other Charges (Recoveries)	The following table details impairment, restructuring and other charges for each of the periods presented (in thousands): Three Months Ended 2024 2023 Asset impairment charges $ 5,492 $ — Restructuring and reorganization charges 821 — Impairment, restructuring and other charges $ 6,313 $ —
Schedule of Restructuring and Other Related Liabilities	The following table summarizes the cash-based restructuring and reorganization related liabilities (in thousands): Balance at December 31, 2023 $ — Restructuring and reorganization charges 821 Payments (180) Balance at March 31, 2024 $ 641

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense	The following table summarizes our benefit from income taxes and our effective tax rates for the periods presented below (in thousands, except effective tax rate): Three Months Ended 2024 2023 Loss before income taxes $ (18,329) $ (23,486) Benefit from income taxes (1,345) (3,608) Effective tax rate 7.3 % 15.4 %

Summary of Business and Signi_3

Summary of Business and Significant Accounting Policies (Details)	Mar. 31, 2024 insurance_carrier
Accounting Policies [Abstract]
Number of health insurance carriers (more than)	180

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Total revenue	$ 92,964	$ 73,723
Medicare
Disaggregation of Revenue [Line Items]
Total revenue	70,159	58,963
Medicare | Medicare Advantage
Disaggregation of Revenue [Line Items]
Total revenue	61,996	54,121
Medicare | Medicare Supplement
Disaggregation of Revenue [Line Items]
Total revenue	5,478	4,065
Medicare | Medicare Part D
Disaggregation of Revenue [Line Items]
Total revenue	2,685	777
Individual and Family
Disaggregation of Revenue [Line Items]
Total revenue	3,691	4,006
Individual and Family | Non-Qualified Health Plans
Disaggregation of Revenue [Line Items]
Total revenue	1,645	2,355
Individual and Family | Qualified Health Plans
Disaggregation of Revenue [Line Items]
Total revenue	2,046	1,651
Ancillary
Disaggregation of Revenue [Line Items]
Total revenue	2,688	2,422
Ancillary | Short-term
Disaggregation of Revenue [Line Items]
Total revenue	388	984
Ancillary | Dental
Disaggregation of Revenue [Line Items]
Total revenue	877	710
Ancillary | Vision
Disaggregation of Revenue [Line Items]
Total revenue	689	210
Ancillary | Other
Disaggregation of Revenue [Line Items]
Total revenue	734	518
Small Business
Disaggregation of Revenue [Line Items]
Total revenue	3,616	4,873
Commission Bonus and Other
Disaggregation of Revenue [Line Items]
Total revenue	773	(2,261)
Total Commission Revenue
Disaggregation of Revenue [Line Items]
Total revenue	80,927	68,003
Other Revenue
Disaggregation of Revenue [Line Items]
Total revenue	12,037	5,720
Other Revenue | Sponsorship and Advertising Revenue
Disaggregation of Revenue [Line Items]
Total revenue	10,189	4,020
Other Revenue | Other
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,848	$ 1,700

Revenue - Commission Revenue by

Revenue - Commission Revenue by Segment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Total revenue	$ 92,964,000	$ 73,723,000
Basic (in dollars per share)	$ (0.96)	$ (1.01)
Diluted (in dollars per share)	$ (0.96)	$ (1.01)
Commission
Disaggregation of Revenue [Line Items]
Total revenue	$ 80,927,000	$ 68,003,000
Commission revenue from members approved during the period
Disaggregation of Revenue [Line Items]
Total revenue	75,429,000	63,325,000
Commission revenue from renewals of small business members during the period
Disaggregation of Revenue [Line Items]
Total revenue	3,028,000	3,113,000
Total net commission revenue from members approved in prior periods
Disaggregation of Revenue [Line Items]
Total revenue	$ 2,470,000	$ 1,565,000
Basic (in dollars per share)	$ 0.06	$ 0.04
Diluted (in dollars per share)	$ 0.06	$ 0.04
Change in revenue	$ (500,000)	$ 0
Medicare | Commission
Disaggregation of Revenue [Line Items]
Total revenue	70,754,000	56,669,000
Medicare | Commission revenue from members approved during the period
Disaggregation of Revenue [Line Items]
Total revenue	69,752,000	56,617,000
Medicare | Commission revenue from renewals of small business members during the period
Disaggregation of Revenue [Line Items]
Total revenue	0
Medicare | Total net commission revenue from members approved in prior periods
Disaggregation of Revenue [Line Items]
Total revenue	1,002,000	52,000
Employer and Individual | Commission
Disaggregation of Revenue [Line Items]
Total revenue	10,173,000	11,334,000
Employer and Individual | Commission revenue from members approved during the period
Disaggregation of Revenue [Line Items]
Total revenue	5,677,000	6,708,000
Employer and Individual | Commission revenue from renewals of small business members during the period
Disaggregation of Revenue [Line Items]
Total revenue	3,028,000	3,113,000
Employer and Individual | Total net commission revenue from members approved in prior periods
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,468,000	$ 1,513,000

Supplemental Financial Statem_3

Supplemental Financial Statement Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Cash	$ 19,865	$ 7,114
Cash equivalents	155,121	108,608
Cash and cash equivalents	174,986	115,722
Restricted cash	3,090	3,090
Total cash, cash equivalents and restricted cash	$ 178,076	$ 118,812	$ 183,872	$ 147,640

Supplemental Financial Statem_4

Supplemental Financial Statement Information - Narrative (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Cash and Cash Equivalents [Line Items]
Restricted cash	$ 3,090,000	$ 3,090,000
Write-off	0	$ 0
China
Cash and Cash Equivalents [Line Items]
Deposits	$ 3,900,000

Supplemental Financial Statem_5

Supplemental Financial Statement Information - Schedule of Allowance for Credit Loss (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 2,118	$ 2,398
Change in allowance	(251)	(280)
Ending balance	$ 1,867	$ 2,118

Supplemental Financial Statem_6

Supplemental Financial Statement Information - Schedule of Commissions Receivable (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Change in Contract with Customer, Asset [Roll Forward]
Beginning balance	$ 918,177
Total revenue	92,964	$ 73,723
Cash receipts	(154,022)
Net change in credit loss allowance	251
Ending balance	845,333
Medicare Segment
Change in Contract with Customer, Asset [Roll Forward]
Beginning balance	847,332
Cash receipts	(143,722)
Net change in credit loss allowance	230
Ending balance	774,594
E&I Segment
Change in Contract with Customer, Asset [Roll Forward]
Beginning balance	70,845
Cash receipts	(10,300)
Net change in credit loss allowance	21
Ending balance	70,739
Commission revenue from members approved during the period
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	75,429	63,325
Commission revenue from members approved during the period | Medicare Segment
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	69,752	56,617
Commission revenue from members approved during the period | E&I Segment
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	5,677	6,708
Commission revenue from renewals of small business members during the period
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	3,028	3,113
Commission revenue from renewals of small business members during the period | Medicare Segment
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	0
Commission revenue from renewals of small business members during the period | E&I Segment
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	3,028	3,113
Net commission revenue from members approved in prior periods
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	2,470	1,565
Net commission revenue from members approved in prior periods | Medicare Segment
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	1,002	52
Net commission revenue from members approved in prior periods | E&I Segment
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	$ 1,468	$ 1,513

Supplemental Financial Statem_7

Supplemental Financial Statement Information - Schedule of Credit Risk (Details) - Customer Concentration Risk - Accounts Receivable	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Humana
Concentration Risk [Line Items]
Major customer revenue, percentage	28%	27%
UnitedHealthCare
Concentration Risk [Line Items]
Major customer revenue, percentage	26%	26%
Aetna
Concentration Risk [Line Items]
Major customer revenue, percentage	16%	16%

Supplemental Financial Statem_8

Supplemental Financial Statement Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Prepaid software and maintenance contracts	$ 5,876	$ 5,328
Prepaid licenses	2,007	2,739
Prepaid expenses	1,287	1,808
Prepaid insurance	849	1,436
Other current assets	987	733
Prepaid expenses and other current assets	$ 11,006	$ 12,044

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets
Short-term marketable securities	$ 13,946	$ 5,930
Commercial paper
Assets
Short-term marketable securities	13,946
Agency bonds
Assets
Short-term marketable securities		5,930
Recurring | Level 1
Assets
Total assets measured at fair value	17,010	11,576
Recurring | Level 2
Assets
Total assets measured at fair value	152,057	102,962
Recurring | Level 3
Assets
Total assets measured at fair value	0	0
Recurring | Carrying Value
Assets
Total assets measured at fair value	169,067	114,538
Recurring | Fair Value
Assets
Total assets measured at fair value	169,067	114,538
Recurring | Commercial paper | Level 1
Assets
Short-term marketable securities	0
Recurring | Commercial paper | Level 2
Assets
Short-term marketable securities	13,946
Recurring | Commercial paper | Level 3
Assets
Short-term marketable securities	0
Recurring | Commercial paper | Carrying Value
Assets
Short-term marketable securities	13,946
Recurring | Commercial paper | Fair Value
Assets
Short-term marketable securities	13,946
Recurring | Agency bonds | Level 1
Assets
Short-term marketable securities		0
Recurring | Agency bonds | Level 2
Assets
Short-term marketable securities		5,930
Recurring | Agency bonds | Level 3
Assets
Short-term marketable securities		0
Recurring | Agency bonds | Carrying Value
Assets
Short-term marketable securities		5,930
Recurring | Agency bonds | Fair Value
Assets
Short-term marketable securities		5,930
Recurring | Money market funds | Level 1
Assets
Cash equivalents	17,010	11,576
Recurring | Money market funds | Level 2
Assets
Cash equivalents	0	0
Recurring | Money market funds | Level 3
Assets
Cash equivalents	0	0
Recurring | Money market funds | Carrying Value
Assets
Cash equivalents	17,010	11,576
Recurring | Money market funds | Fair Value
Assets
Cash equivalents	17,010	11,576
Recurring | Commercial paper | Level 1
Assets
Cash equivalents	0	0
Recurring | Commercial paper | Level 2
Assets
Cash equivalents	110,718	86,090
Recurring | Commercial paper | Level 3
Assets
Cash equivalents	0	0
Recurring | Commercial paper | Carrying Value
Assets
Cash equivalents	110,718	86,090
Recurring | Commercial paper | Fair Value
Assets
Cash equivalents	110,718	86,090
Recurring | Agency bonds | Level 1
Assets
Cash equivalents	0	0
Recurring | Agency bonds | Level 2
Assets
Cash equivalents	27,393	10,942
Recurring | Agency bonds | Level 3
Assets
Cash equivalents	0	0
Recurring | Agency bonds | Carrying Value
Assets
Cash equivalents	27,393	10,942
Recurring | Agency bonds | Fair Value
Assets
Cash equivalents	$ 27,393	$ 10,942

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Contractual Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Amortized Cost
Due in 1 year	$ 169,130	$ 114,577
Fair Value
Due in 1 year	$ 169,067	$ 114,538

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Unrealized Gains and Losses (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Cash equivalents
Fair Value	$ 155,121	$ 108,608
Short-term marketable securities
Fair Value	13,946	5,930
Total	169,130	114,577
Unrealized Gains	0	3
Unrealized Losses	(63)	(42)
Fair Value	169,067	114,538
Commercial paper
Short-term marketable securities
Amortized Cost	13,954
Unrealized Gains	0
Unrealized Losses	(8)
Fair Value	13,946
Agency bonds
Short-term marketable securities
Amortized Cost		5,929
Unrealized Gains		1
Unrealized Losses		0
Fair Value		5,930
Money market funds
Cash equivalents
Amortized Cost	17,010	11,576
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	17,010	11,576
Commercial paper
Cash equivalents
Amortized Cost	110,773	86,132
Unrealized Gains	0	0
Unrealized Losses	(55)	(42)
Fair Value	110,718	86,090
Agency bonds
Cash equivalents
Amortized Cost	27,393	10,940
Unrealized Gains	0	2
Unrealized Losses	0	0
Fair Value	$ 27,393	$ 10,942

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) security	Mar. 31, 2023 USD ($)	Dec. 31, 2023 security
Fair Value Disclosures [Abstract]
Number of securities in net loss positions | security	41		20
Interest income | $	$ 2.2	$ 1.9

Equity - Narrative (Details)

Equity - Narrative (Details) - shares shares in Millions	1 Months Ended		3 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Mar. 31, 2024	Mar. 31, 2023	Sep. 22, 2021
Equity, Class of Treasury Stock [Line Items]
Treasury stock (in shares)			13	12.5
Treasury shares that were previously surrendered by employees to satisfy tax withholdings (in shares)			2.3	1.8
2021 Inducement Plan
Equity, Class of Treasury Stock [Line Items]
Shares reserved for future issuance (in shares)					0.4
Additional shares reserved (in shares)	1.5	0.5
Granted (in shares)			2
Previous share repurchase programs
Equity, Class of Treasury Stock [Line Items]
Number of shares repurchased under share repurchase plan (in shares)			10.7

Equity - Schedule of Stock-Base

Equity - Schedule of Stock-Based Compensation Expense By Award Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 5,540	$ 4,994
Related tax benefit recognized	1,312	1,170
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	4,636	4,073
Performance-based stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	407	604
Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	400	254
Employee stock purchase program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 97	$ 63

Equity - Schedule of Stock-Ba_2

Equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 5,540	$ 4,994
Amount capitalized for internal-use software	178	312
Total stock-based compensation	5,718	5,306
Marketing and advertising
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	644	455
Customer care and enrollment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	524	605
Technology and content
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	974	905
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 3,398	$ 3,029

Convertible Preferred Stock - N

Convertible Preferred Stock - Narrative (Details) $ / shares in Units, $ in Thousands					3 Months Ended
	Apr. 30, 2024 day	Jun. 30, 2023	Jun. 30, 2021 $ / shares	Apr. 30, 2021 USD ($) vote day state $ / shares shares	Mar. 31, 2024 USD ($) $ / shares shares	Apr. 30, 2027 day	Dec. 31, 2023 USD ($)	Sep. 30, 2023	Aug. 31, 2023	Feb. 17, 2021 USD ($) member
Temporary Equity [Line Items]
Sale of stock, shares issued (in shares) | shares				2,250,000
Preferred stock, par value (in dollars per share) | $ / shares				$ 0.001
Gross proceeds				$ 225,000
Carrying amount				214,000	$ 307,410		$ 298,053
Payments of stock issuance costs				$ 10,975
Dividend rate		8%	8%
Stated value (in dollars per share) | $ / shares			$ 100
Dividend rate, payable-in-kind		6%
Dividend rate, cash		2%
Conversion rate (in dollars per share) | $ / shares					$ 79.5861
Redemption put right, percentage of accrued value					135%
Number of trading days | day				5
Number of votes per share | vote				1
Asset coverage ratio								250%	250%	200%
Shares converted (in shares) | shares					0
Accrued paid-in-kind dividends, common stock equivalent, as-converted (in shares) | shares					3,500,000
Series A Preferred Stock
Temporary Equity [Line Items]
Dividends, cash					$ 1,400
Aggregate accrued value divisor (in dollars per share) | $ / shares				$ 69.684
Minimum
Temporary Equity [Line Items]
Minimum liquidity amount										$ 65,000
Maximum
Temporary Equity [Line Items]
Minimum liquidity amount										$ 125,000
H.I.G
Temporary Equity [Line Items]
Number of nominations to board of directors | state				1
Minimum common stock ownership percentage needed to nominate individual to board of directors				30%
Minimum ownership percentage				30%						30%
Convertible preferred stock, number of additional rights to nominate | member										1
Forecast
Temporary Equity [Line Items]
Redemption put right, percentage of accrued value						135%
Redemption call right, number of days for written notice | day						30
Threshold percentage of conversion price	167.50%
Threshold consecutive trading days | day	20
Threshold trading days | day	30

Convertible Preferred Stock - S

Convertible Preferred Stock - Schedule of Stock (Details) - USD ($) $ in Thousands		3 Months Ended
	Apr. 30, 2021	Mar. 31, 2024
Temporary Equity Disclosure [Abstract]
Gross proceeds	$ 225,000
Less: issuance costs	(10,975)
Net proceeds	214,025
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance		$ 298,053
Accrued paid-in-kind dividends		4,110
Change in preferred stock redemption value		5,247
Ending balance	$ 214,000	$ 307,410

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Numerator:
Net loss attributable to common stockholders basic	$ (27,711)	$ (28,048)
Net loss attributable to common stockholders diluted	$ (27,711)	$ (28,048)
Denominator:
Shares used in per share calculation - basic (in shares)	28,912	27,648
Dilutive effect of common stock (in shares)	0	0
Shares used in per share calculation - diluted (in shares)	28,912	27,648
Net loss attributable to common stockholders per share - basic (in dollars per share)	$ (0.96)	$ (1.01)
Net loss attributable to common stockholders per share - diluted (in dollars per share)	$ (0.96)	$ (1.01)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	5,996	5,395
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	3,469	3,256
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	2,204	1,774
Performance-based stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	97	98
Common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	218	226
Employee stock purchase program
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	8	41

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Obligations (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Contractual Obligation, Fiscal Year Maturity [Abstract]
2024 (remainder)	$ 3,784
2025	1,141
2026	0
2027	0
2028	0
Thereafter	0
Total	$ 4,925

Commitment and Contingencies -

Commitment and Contingencies - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Self insurance reserve, maximum benefits per employee	$ 0.3
Self insurance maximum claim liability	22.5
Self insurance reserve	$ 2	$ 2.5

Segment and Geographic Inform_3

Segment and Geographic Information - Segment Operating Results (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($) segment	Mar. 31, 2023 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | segment	2
Total revenue	$ 92,964	$ 73,723
Stock-based compensation expense	(5,540)	(4,994)
Depreciation and amortization	(4,406)	(5,245)
Impairment, restructuring and other charges	(6,313)	0
Interest expense	(2,809)	(2,580)
Other income, net	2,391	1,988
Loss before income taxes	(18,329)	(23,486)
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	92,964	73,723
Segment profit	12,961	7,088
Operating Segments | Medicare
Segment Reporting Information [Line Items]
Total revenue	82,388	61,834
Segment profit	8,309	(586)
Operating Segments | Employer and Individual
Segment Reporting Information [Line Items]
Total revenue	10,576	11,889
Segment profit	4,652	7,674
Corporate
Segment Reporting Information [Line Items]
Segment profit	$ (14,613)	$ (19,743)

Segment and Geographic Inform_4

Segment and Geographic Information - Schedule of Long-Lived Assets by Geographical Area (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 27,679	$ 29,700
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	27,432	29,419
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 247	$ 281

Segment and Geographic Inform_5

Segment and Geographic Information - Schedule of Revenue by Major Customers (Details) - Customer Concentration Risk - Revenue	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Humana
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	26%	24%
Aetna
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	23%	6%
UnitedHealthCare
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	15%	22%

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Lessee, Lease, Description [Line Items]
Future sublease income	$ 13.1
Impairment charges, excluding capitalized computer software	$ 5.5
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term	2 years
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	6 years

Leases - Operating Lease Costs

Leases - Operating Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Leases [Abstract]
Operating lease expense	$ 1,737	$ 1,855
Operating sublease income	(576)	(577)
Total operating lease cost	$ 1,161	$ 1,278

Leases - Supplemental Informati

Leases - Supplemental Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 2,231	$ 2,102
Weighted-average remaining lease term (in years) of operating leases	4 years 7 months 6 days		4 years 9 months 18 days
Weighted-average discount rate used to recognize operating lease right-of-use-assets	5.70%		5.70%

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Operating leases
2024 (remainder)	$ 6,663
2025	9,099
2026	7,594
2027	6,773
2028	4,998
Thereafter	3,204
Total lease payments	38,331
Less imputed interest	(4,840)
Total	33,491
Sublease income, remainder of 2024	1,800
Sublease income, 2025	2,600
Sublease income, 2026	2,700
Sublease income, 2027	2,800
Sublease income, 2028	2,800
Sublease income, thereafter	$ 1,000

Impairment, Restructuring and_3

Impairment, Restructuring and Other Charges - Impairment, Restructuring and Other Charges (Recoveries) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Asset impairment charges	$ 5,492	$ 0
Restructuring and reorganization charges	821	0
Impairment, restructuring and other charges	$ 6,313	$ 0

Impairment, Restructuring and_4

Impairment, Restructuring and Other Charges - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Restructuring and Related Activities [Abstract]
Asset impairment charges	$ 5,492	$ 0
Impairment charge	5,100
Tangible asset impairment charges	400
Restructuring and reorganization charges	821	$ 0
Accrued restructuring charges	$ 641		$ 0

Impairment, Restructuring and_5

Impairment, Restructuring and Other Charges - Restructuring and Other Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Restructuring Reserve [Roll Forward]
Balance at December 31, 2023	$ 0
Restructuring and reorganization charges	821	$ 0
Payments	(180)
Balance at March 31, 2024	$ 641

Debt (Details)

Debt (Details) - USD ($)			3 Months Ended
	Aug. 16, 2022	Feb. 28, 2022	Mar. 31, 2024	Mar. 31, 2023
Debt Instrument [Line Items]
Interest expense			$ 2,809,000	$ 2,580,000
Secured Debt | Term Loan Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 70,000,000
Debt issuance costs		5,100,000
Amortization of debt issuance costs			400,000	400,000
Unamortized issuance costs			1,800,000
Carrying value of loan			$ 68,200,000
Interest rate			13.10%
Interest expense			$ 2,300,000	$ 2,200,000
Annual agreement fee		300,000
Minimum liquidity		$ 25,000,000
Outstanding amount as a percentage of total contract assets - commissions receivables (less than)		50%
Secured Debt | Term Loan Credit Agreement | Line of Credit | Federal Funds Rate
Debt Instrument [Line Items]
Basis spread on interest rate	0.50%	0.50%
Secured Debt | Term Loan Credit Agreement | Line of Credit | London Interbank Offered Rate
Debt Instrument [Line Items]
Basis spread on interest rate		1%
Interest rate		7.50%
Secured Debt | Term Loan Credit Agreement | Line of Credit | Base Rate
Debt Instrument [Line Items]
Interest rate	6.50%	6.50%
Secured Debt | Term Loan Credit Agreement | Line of Credit | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Basis spread on interest rate	1%
Interest rate	7.50%

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Benefit (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (18,329)	$ (23,486)
Benefit from income taxes	$ (1,345)	$ (3,608)
Effective tax rate	7.30%	15.40%

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Benefit from income taxes	$ 1,345	$ 3,608
Effective tax rate	7.30%	15.40%